Choosing an Inflammation Marker: hs-CRP, PCT and IL-6

Updated 2026-09-28

hs-CRP, procalcitonin and interleukin-6 report different aspects of the inflammatory response. A guide to selecting the right analyte.

Three Markers, Three Signals

hs-CRP, procalcitonin (PCT) and interleukin-6 (IL-6) are not competing versions of one measurement. C-reactive protein is an acute-phase protein produced by the liver, and high-sensitivity CRP detects the low-grade elevations associated with cardiovascular risk assessment. PCT is a peptide precursor whose concentration rises with certain bacterial infections. IL-6 is a cytokine that rises earlier in the inflammatory cascade. Each reflects a different point in the response, so the choice of marker depends on the question being asked.

Where Each Marker Is Useful

hs-CRP is used to assess chronic low-grade inflammation and to support cardiovascular risk stratification. PCT has been studied as an aid in distinguishing bacterial from non-bacterial inflammation and is used in some settings to inform antibiotic decisions. IL-6 rises rapidly after an inflammatory stimulus and can be measured in serum, plasma and cell culture, which makes it useful in both clinical research and basic immunology. The intended use governs the specification far more than any general ranking of the three. None of the three replaces clinical judgement, and all are described here for research and assay-development use.

Selection for Assay Development

For a new assay, the decision is driven by the sample type, the required sensitivity and the dynamic range. IL-6 assays often need a broad working range and careful control of non-specific binding; PCT assays require attention to glycosylation and to the mature and precursor forms; hs-CRP demands high sensitivity because the reference range is low. Pepys and Hirschfield summarised the biology of CRP in the Journal of Clinical Investigation (2003), and Assicot and colleagues described PCT in sepsis in The Lancet (1993).

Kinetics decide which marker you can measure at all

The three markers rise and fall on different timescales, and that single fact eliminates options before any consideration of sensitivity. IL-6 moves first, rising within hours of an inflammatory stimulus, which makes it useful for detecting an acute event but also makes sampling time part of the experiment. C-reactive protein follows over roughly a day and then declines slowly, which is why it is well suited to serial monitoring and to low-grade chronic elevation. Procalcitonin sits between the two in timing and has been studied extensively as an aid to decisions about antibiotics in respiratory infection, which is a different clinical question from measuring inflammation in general. If your protocol fixes a single sampling point, the marker whose concentration is changing fastest at that moment is a poor choice regardless of its analytical quality. Deciding the sampling schedule and the marker together is the only way to avoid that outcome.

How the specifications differ between the three assays

The specification that dominates changes with the analyte. For a high-sensitivity CRP assay the challenge is the low end of the range, since the reference concentrations are small and non-specific binding is a large fraction of the signal — so background control and a well-defined calibrator matrix matter more than maximum purity. For procalcitonin, the analytical question is which forms the antibody reads and whether the calibrator presents them consistently, since the analyte exists as a precursor with a modified biology rather than as a single mature peptide. For IL-6, dynamic range is the constraint, because concentrations in cell-culture supernatants and in serum can differ by orders of magnitude, and a pair that is excellent across two decades may be useless in the third. Matching the specification to the dominant risk of that particular assay is more productive than applying one purity standard to all three.

Ask a technical question